NKTX
Nkarta Inc
1 day chart
About NKTX
Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. The Company’s product candidates include NKX101 and NKX019, which are in ongoing Phase I clinical trials. NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy donors. It is engineered with a chimeric antigen receptor (CAR) targeting NKG2D ligands on tumor cells. NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed CAR for enhanced tumor cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support.
Buy US stocks in Australia starting with NKTX. Open an account and start investing today!
$78.98M
-
0.00%
0
$1.63
$1.53
$0.00
$14.57
$1.55
NKTX FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in NKTX
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.